Our Work

Below, we’ve provided highlights showcasing how much the International Eczema Council has achieved since inception.  


2024 Planned Events

We are planning five in-person educational symposia in 2024! Attendance is complimentary and live symposia are recorded to create easily accessible, enduring educational content on our website. On-demand education remains available to clinicians worldwide at their convenience. The programs for 2024 are:

  • Industry gatherings will be held in conjunction with our educational symposia. When you join one of our IEC Corporate Councils, you’ll be invited to take part in these special events that bring together important members of industry like you with the global AD leaders from around the world. Meeting face to face, you’ll discuss current issues, including work being undertaken by the IEC at the time, and have time to ask questions of our Leadership. These  meetings give the experts on both sides—industry professionals and clinical/research experts—to check in on current AD treatment work, developments, concerns, and needs from the top minds around the world. 

2023 Highlights:

  • Seven live symposia on four continents (Asia, Europe, North America, and South America):

2022 Highlights:

  • Report on the Global Burden of Atopic Dermatitis Launched October 18, 2022: The IEC collaborated to launch the Global Atopic Dermatitis Atlas (GADA; atopicdermatitisatlas.org), the first report on the global burden of atopic dermatitis. The project was led by Carsten Flohr, a member of the IEC Board of Directors, and was the result of collaboration between the IEC, the International Society for Atopic Dermatitis, the European Taskforce for Atopic Dermatitis, the International League of Dermatological Societies, and the International Alliance of Dermatology Patient Organizations (Global Skin). GADA summarizes the disease burden, impact on patients’ and their families’ lives, geographical gaps in prevalence data, and available treatments. It assesses inequalities in access to therapeutics in lower resource settings and provides horizon scanning on novel treatment approaches.

2021 Highlights: 

2020 Highlights:

2019 Highlights:

2018 Highlights:

2017 Highlights:

2016 Highlights: 



In addition to live symposia, IEC hosts Councilor and Associate meetings at major dermatological meetings each year. During this time, Councilors and Associates discuss their work, including research, trends, advances, and regional differences. When these meetings are used to determine and resolve knowledge gaps, the results are typically developed as manuscripts intended for publication in high-impact prestigious journals. This ensures the work of our experts is disseminated to advance patient care worldwide.

IEC Councilor sessions have been held or are planned to study and develop manuscripts on many cutting-edge topics, including the Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA AD), skin of color, AD biomarkers, the effects of climate and environment on AD, and difficult-to-treat populations.

Published IEC Manuscripts



  • The IEC launched a fellowship program in 2021 to provide qualified candidates with opportunities to work with expert AD dermatologists (IEC Councilors) in clinical and research settings. In 2022, the IEC arranged two clinical fellowships. Currently, the program matches fellows from around the world with IEC Councilors in the USA, and work is underway to expand the program into Canada. In 2023, we chose the first IEC Fellow for our new research fellowship program in partnership with the Montreal Dermatology Research Institute. Taking place in Canada, this is our second fellowship program but our first outside of the US. The IEC Fellowship program also welcomed its second round of fellows to the US in 2023 for clinical and research positions. Both programs encourage international and local applicants. Inaugural participants have praised the new program. Please contact IEC CEO Alan Stiles if you would like to fund a fellowship opportunity. Learn More
  • Dr. Fabio Nunes and Eli Lilly and Company spearheaded the project to develop the validated Investigator’s Global Assessment for Atopic Dermatitis (vIGA-ADTM) scale in which many other pharma companies joined in (e.g., Galderma, Abbvie.) More than a dozen IEC members developed a new IGA, calibrated it, validated it, and made it a teaching program so that it can be widely used for clinical trials. Access the scale.
  • The IEC’s educational modules for AD clinical investigators were developed by Eric Simpson and GlaxoSmithKline LLC, who have made them available to the IEC. The topic areas covered are: 1) Calculating % Body Surface Area (BSA) and Eczema Area Severity Index (EASI) Score, and 2) Target Lesion Severity Score (TLSS) for the Assessment of AD. The content of the modules can be viewed with certified training available at ieclearning.com through WCG Trifecta. The IEC appreciates the following for making these resources available to the clinical community: Steve Frey, Tomoko Maeda-Chubachi, Eric Simpson, Fabio P. Nunes, Eli Lilly and Company, and GlaxoSmithKline LLC. These modules are undergoing revision and updating via a renewed contract with our colleagues at WCG Trifecta.
  • The IEC has posted ranked AD-related publications each year to provide professionals with quick access to the most important journal articles on the topic, as determined by IEC Councilors and Associates. View the Top Atopic Dermatitis Articles